RGEN: Rounding Bottom detected on 19 Aug 2026

RGEN is forming a rounding bottom pattern with a structure score of 14/15 and strong breakout potential (13/13). The stock trades at $166.15, sitting 5.5% below its 52-week high of $171.02 (near-term resistance) while maintaining 64.5% gains from its 52-week low. The measured move target is $173.35—a modest 4.3% upside from current levels. With a win probability of 66%, the setup suggests moderate technical conviction. However, volume remains a concern: current volume of 462,720 shares is just 37% of the 20-day average, indicating limited participation in pattern formation. The rounding bottom structure appears intact, but shallow.

In Q2 2026, Repligen achieved 12% reported revenue growth and 13% organic growth, with a 55% increase in adjusted operating income, and raised full-year organic revenue guidance to 10.5%-13.5% and adjusted EPS to $2.03-$2.09. The Proteins segment surged 50% and Asia Pacific led with 40% revenue growth. In July 2026, Repligen announced the acquisition of BioLife Solutions, expanding cell therapy capabilities, a strategic move to access high-growth markets. The company divested its non-core filtration business to accelerate focus on profitable growth. This confluence of accelerating organic growth, margin expansion, strategic acquisitions, and raised guidance is driving sentiment and explains the 59% gain over three months into the pattern consolidation.

A confirmed breakout above the $171.02 resistance level would target $173.35 conservatively—representing a 4.3% move. Historically, rounding bottoms with 66% win probability suggest successful breakouts about two-thirds of the time. Volume confirmation is critical: the setup requires a surge above the 20-day average of 1.25M shares to validate the breakout. The invalidation level sits at $100.99 (the key support floor), which is 39% below current price—a significant buffer. If the stock fails to clear $171 or closes decisively below $161, the pattern deteriorates. The bullish regime (0.95 score) and health care sector strength (0.95 regime score) provide favorable structural tailwinds for an upside resolution.

Recent insider activity shows net selling, a caution flag even as fundamentals improve. The RSI of 66.7 approaches overbought territory (70+), suggesting limited room for momentum-driven continuation without consolidation. Volume participation at 37% of average is abnormally weak, raising questions about conviction—a breakout on low volume is vulnerable to reversal. Beta of 0.42 indicates lower volatility, but this also means breakout acceleration may be muted. The company faces challenges converting orders to revenue quickly, particularly in capital equipment, due to customer preparedness and site readiness, a fundamental headwind that could disappoint near-term earnings. The BioLife acquisition integration risk and near-term capital deployment remain unknowns.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.